or Try an Advanced Search...

    Refractory Acute Myeloid Leukemia Stocks List

    Symbol Grade Name % Change
    XBIO B Xenetic Biosciences, Inc. 0.37
    SYRS D Syros Pharmaceuticals, Inc. -10.12
    CRBU D Caribou Biosciences, Inc. 12.76
    MBRX F Moleculin Biotech, Inc. -5.77
    View As Page of Charts
    Related Industries: Biotechnology
    Related Stock Lists: Acute Myeloid Leukemia Biopharmaceutical Biotechnology Cancer Leukemia Medicine Treatment Of Relapsed Or Refractory Acute Myeloid Leukemia Acute Leukemia Anemia Antineoplastic Drugs Blastoma Breakthrough Therapy CD19 Cancer Immunotherapy Cell Biology Cell Therapy Chemotherapy Chimeric Antigen Receptor T Cell Chronic Kidney Disease Clinical Medicine

    Related ETFs - A few ETFs which own one or more of the above listed Refractory Acute Myeloid Leukemia stocks.

    Symbol Grade Name Weight
    CNCR F Loncar Cancer Immunotherapy ETF 1.28
    WDNA D WisdomTree BioRevolution Fund 0.46
    NXTE B AXS Green Alpha ETF 0.38
    GNOM F Global X Genomics & Biotechnology ETF 0.26
    IWC B iShares Microcap ETF 0.05
    View all Refractory Acute Myeloid Leukemia ETFs...
    Compare ETFs
    Compare CNCR to GNOM Compare CNCR to NXTE Compare NXTE to IWC

        Refractory Acute Myeloid Leukemia Stocks Recent News

        Date Stock Title
        Nov 1 SYRS Syros Pharmaceuticals Inc (SYRS) Q3 2024 Earnings Call Highlights: Strategic Focus on ...
        Oct 31 SYRS Syros Pharmaceuticals, Inc (SYRS) Q3 2024 Earnings Call Transcript
        Oct 31 SYRS Syros Pharmaceuticals GAAP EPS of -$0.16 beats by $0.52
        Oct 31 SYRS Syros Reports Third Quarter 2024 Financial Results and Provides a Business Update
        Oct 31 CRBU Is Caribou Biosciences (CRBU) a Promising Gene Editing Stock?
        Oct 30 SYRS Syros Pharmaceuticals Q3 2024 Earnings Preview
        Related Industries: Biotechnology
        Related Stock Lists: Acute Myeloid Leukemia Biopharmaceutical Biotechnology Cancer Leukemia Medicine Treatment Of Relapsed Or Refractory Acute Myeloid Leukemia Acute Leukemia Anemia Antineoplastic Drugs Blastoma Breakthrough Therapy CD19 Cancer Immunotherapy Cell Biology Cell Therapy Chemotherapy Chimeric Antigen Receptor T Cell Chronic Kidney Disease Clinical Medicine
        Refractory Acute Myeloid Leukemia

        Refractory Acute Myeloid Leukemia (AML) is a type of cancer of the blood and bone marrow that is resistant to standard treatments. It is a rare and aggressive form of leukemia that is difficult to treat and has a poor prognosis. Symptoms of AML include fatigue, fever, weight loss, and anemia. Treatment options for refractory AML include chemotherapy, stem cell transplant, and targeted therapies.

        Browse All Tags